Vir Biotechnology, Inc. (VIR)
Sector: Healthcare
Industry: Biological Products, (No Diagnostic Substances)
Country: United States
Exchange: NASDAQ
Market cap: $1.80B
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Latest financial period: June 30, 2026
Filed with the SEC: August 5, 2026
Estimated earnings date: November 4, 2026
Profit #1369 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 5.9% | 3.6% | 4.0% | 4.1% |
Growth #19 of 1484 companies
Payout #1117 of 1484 companies
Safety #796 of 1484 companies
Price #1462 of 1484 companies
